Skip to main content

Table 3 Comparison of the clinical parameters and splenic T cell populations in EAE-Vehicle, and EAE-FTY720 responder and non-responder mice

From: Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis

 

EAE-Vehicle

EAE-FTY720

p value

Non-responder

Responder

Clinical parameters

 Maximum score

3

(2.25–3)

3

(3–3)

2.25*

(1.25–2.63)

 < 0.01

 dpi peak

15

(14–17)

15

(13–15)

15

(14–16)

ns

 Severity index

0.75

(0.50–1)

0.75

(0.60–1)

0.63

(0.33–0.69)

ns

 Peak accumulated score

6.5

(5.63–9)

7

(6.50–9.75)

4.5*

(3–6.63)

 < 0.05

 Total accumulated score

37.25

(23–45.38)

41.38

(34.38–45.50)

18*

(10.90–24.75)

 < 0.001

 % Recovery

25

(12.5–33.30)

8.33

(0–25)

75*

(62.50–80.95)

 < 0.001

 Recovery index

0.09

(0.04–0.17)

0.04

(0–0.09)

0.17*

(0.13–0.22)

 < 0.01

 Residual score

2.25

(1–2.63)

2.75

(2.25–3)

0.5*

(0.5–0.75)

 < 0.001

Spleen

 % CD3+/Total blood cells

15.15 ± 0.97

15.68 ± 3.27

10.13 ± 0.77*

 < 0.01

 % CD4+/Total blood cells

9.11 ± 0.64

10.51 ± 2.17

7.20 ± 0.56*

 < 0.05

 % CD8+/Total blood cells

4.98 ± 0.36

4.47 ± 0.91

2.46 ± 0.21*

 < 0.001

 % CD3 CD25+/Total blood cells

1.32 ± 0.08

1.33 ± 0.25

1.04 ± 0.07*

 < 0.05

 % CD3 CD69+/Total blood cells

1.77 ± 0.12

2.24 ± 0.31

1.78 ± 0.10

ns

  1. The data are expressed as the median (IQR). One-way ANOVA or a non-parametric ANOVA on ranks tests are shown: dpi day post-immunization; ns not significant; IQR interquartile range
  2. *Represents significantly different groups